List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8360107/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Classification and basic pathology of Alzheimer disease. Acta Neuropathologica, 2009, 118, 5-36.	7.7	805
2	Enrichment or depletion of a GO category within a class of genes: which test?. Bioinformatics, 2007, 23, 401-407.	4.1	630
3	Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathologica, 2008, 115, 5-38.	7.7	365
4	Behavioural and psychological symptoms ofÂdementia in Down syndrome: Early indicators ofÂclinical Alzheimer's disease?. Cortex, 2015, 73, 36-61.	2.4	201
5	CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease. Brain, 2015, 138, 2383-2398.	7.6	163
6	Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. Lancet Neurology, The, 2018, 17, 335-346.	10.2	161
7	Local cholesterol increase triggers amyloid precursor proteinâ€Bacel clustering in lipid rafts and rapid endocytosis. FASEB Journal, 2011, 25, 1295-1305.	0.5	153
8	Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 764-775.	0.8	122
9	Clathrin adaptor CALM/PICALM is associated with neurofibrillary tangles and is cleaved in Alzheimer's brains. Acta Neuropathologica, 2013, 125, 861-878.	7.7	107
10	Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology. Human Molecular Genetics, 2015, 24, 5965-5976.	2.9	96
11	Trisomy for Synaptojanin1 in Down syndrome is functionally linked to the enlargement of early endosomes. Human Molecular Genetics, 2012, 21, 3156-3172.	2.9	92
12	Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. Alzheimer's and Dementia, 2018, 14, 1204-1215.	0.8	79
13	Hypoxanthine-guanine phosphoribosyl transferase regulates early developmental programming of dopamine neurons: implications for Lesch-Nyhan disease pathogenesis. Human Molecular Genetics, 2009, 18, 2317-2327.	2.9	78
14	Clathrin-dependent APP endocytosis and Aβ secretion are highly sensitive to the level of plasma membrane cholesterol. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 846-852.	2.4	77
15	Increasing membrane cholesterol of neurons in culture recapitulates Alzheimer's disease early phenotypes. Molecular Neurodegeneration, 2014, 9, 60.	10.8	76
16	Level of PICALM, a key component of clathrin-mediated endocytosis, is correlated with levels of phosphotau and autophagy-related proteins and is associated with tau inclusions in AD, PSP and Pick disease. Neurobiology of Disease, 2016, 94, 32-43.	4.4	66
17	Inside Alzheimer brain with CLARITY: senile plaques, neurofibrillary tangles and axons in 3-D. Acta Neuropathologica, 2014, 128, 457-459.	7.7	64
18	Conserved meningeal lymphatic drainage circuits in mice and humans. Journal of Experimental Medicine, 2022, 219, .	8.5	54

#	Article	IF	CITATIONS
19	Global/temporal gene expression in diaphragm and hindlimb muscles of dystrophin-deficient (mdx) mice. American Journal of Physiology - Cell Physiology, 2002, 283, C773-C784.	4.6	53
20	Treating enhanced GABAergic inhibition in Down syndrome: Use of GABA α5-selective inverse agonists. Neuroscience and Biobehavioral Reviews, 2014, 46, 218-227.	6.1	52
21	Chronic Treatment with a Promnesiant GABA-A -Selective Inverse Agonist Increases Immediate Early Genes Expression during Memory Processing in Mice and Rectifies Their Expression Levels in a Down Syndrome Mouse Model. Advances in Pharmacological Sciences, 2011, 2011, 1-11.	3.7	51
22	Gene expression signature of cerebellar hypoplasia in a mouse model of Down syndrome during postnatal development. BMC Genomics, 2009, 10, 138.	2.8	50
23	DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives. Scientific Reports, 2018, 8, 2859.	3.3	49
24	Patterns and severity of vascular amyloid in Alzheimer's disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer's disease. Acta Neuropathologica, 2018, 136, 569-587.	7.7	47
25	Down syndrome gene dosage imbalance on cerebellum development. Progress in Neurobiology, 2007, 82, 87-94.	5.7	46
26	The prion-like propagation hypothesis in Alzheimer's and Parkinson's disease. Current Opinion in Neurology, 2019, 32, 266-271.	3.6	45
27	Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 940-950.	0.8	43
28	Homodimerization of Amyloid Precursor Protein at the Plasma Membrane: A homoFRET Study by Time-Resolved Fluorescence Anisotropy Imaging. PLoS ONE, 2012, 7, e44434.	2.5	42
29	Excess Synaptojanin 1 Contributes to Place Cell Dysfunction and Memory Deficits in the Aging Hippocampus in Three Types of Alzheimer's Disease. Cell Reports, 2018, 23, 2967-2975.	6.4	41
30	Cholesterol changes in Alzheimer's disease: methods of analysis and impact on the formation of enlarged endosomes. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 839-845.	2.4	39
31	Analysis of gene expression at the single-cell level using microdroplet-based microfluidic technology. Biomicrofluidics, 2011, 5, 024109.	2.4	38
32	Role of cholesterol metabolism in the pathogenesis of Alzheimer's disease. Current Opinion in Clinical Nutrition and Metabolic Care, 2014, 17, 319-323.	2.5	38
33	Screening for SARS-CoV-2 by RT-PCR: Saliva or nasopharyngeal swab? Rapid review and meta-analysis. PLoS ONE, 2021, 16, e0253007.	2.5	38
34	Proliferation deficits and gene expression dysregulation in Down's syndrome (Ts1Cje) neural progenitor cells cultured from neurospheres. Journal of Neuroscience Research, 2009, 87, 3143-3152.	2.9	37
35	Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact. Brain, 2009, 132, 2219-2230.	7.6	36
36	GABAergic over-inhibition, a promising hypothesis for cognitive deficits in Down syndrome. Free Radical Biology and Medicine, 2018, 114, 33-39.	2.9	36

#	Article	IF	CITATIONS
37	Multi-omics signature of brain amyloid deposition in asymptomatic individuals at-risk for Alzheimer's disease: The INSIGHT-preAD study. EBioMedicine, 2019, 47, 518-528.	6.1	36
38	Demonstration of the partial agonist profiles of Ro 16-6028 and Ro 17-1812 in mice in vivo. European Journal of Pharmacology, 1988, 156, 169-172.	3.5	34
39	Alterations of specific cortical GABAergic circuits underlie abnormal network activity in a mouse model of Down syndrome. ELife, 2020, 9, .	6.0	31
40	Nanoroughened plasmonic films for enhanced biosensing detection. Nanotechnology, 2009, 20, 225502.	2.6	30
41	Relationship between Basal Forebrain Resting-State Functional Connectivity and Brain Amyloid-β Deposition in Cognitively Intact Older Adults with Subjective Memory Complaints. Radiology, 2019, 290, 167-176.	7.3	30
42	Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study. Neurobiology of Aging, 2020, 90, 43-59.	3.1	30
43	Specific Susceptibility to COVID-19 in Adults with Down Syndrome. NeuroMolecular Medicine, 2021, 23, 561-571.	3.4	30
44	Longâ€lasting correction of in vivo LTP and cognitive deficits of mice modelling Down syndrome with an α5â€selective GABA _A inverse agonist. British Journal of Pharmacology, 2020, 177, 1106-1118.	5.4	27
45	Picalm reduction exacerbates tau pathology in a murine tauopathy model. Acta Neuropathologica, 2020, 139, 773-789.	7.7	27
46	Ultrastructural and dynamic studies of the endosomal compartment in Down syndrome. Acta Neuropathologica Communications, 2020, 8, 89.	5.2	27
47	Reducing Gabaergic Inhibition Restores Cognitive Functions in a Mouse Model of Down Syndrome. CNS and Neurological Disorders - Drug Targets, 2014, 13, 8-15.	1.4	25
48	A High-Resolution Physical Map of Human Chromosome 21p Using Yeast Artificial Chromosomes. Genome Research, 1999, 9, 1059-1073.	5.5	23
49	Time-gated total internal reflection fluorescence microscopy with a supercontinuum excitation source. Applied Optics, 2009, 48, 553.	2.1	22
50	The amyloid precursor protein is a conserved Wnt receptor. ELife, 2021, 10, .	6.0	22
51	Presynaptic APP levels and synaptic homeostasis are regulated by Akt phosphorylation of huntingtin. ELife, 2020, 9, .	6.0	21
52	Effect of Alzheimer's disease risk and protective factors on cognitive trajectories in subjective memory complainers: An INSIGHTâ€preAD study. Alzheimer's and Dementia, 2018, 14, 1126-1136.	0.8	20
53	Alzheimer's Disease: Tau Pathology and Dysfunction of Endocytosis. Frontiers in Molecular Neuroscience, 2020, 13, 583755.	2.9	19
54	Vaccination with Sarkosyl Insoluble PHF-Tau Decrease Neurofibrillary Tangles Formation in Aged Tau Transgenic Mouse Model: A Pilot Study. Journal of Alzheimer's Disease, 2014, 40, S135-S145.	2.6	18

#	Article	IF	CITATIONS
55	Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer's disease and not in other tauopathies. Acta Neuropathologica Communications, 2019, 7, 195.	5.2	18
56	Changing Paradigms in Down Syndrome: The First International Conference of the Trisomy 21 Research Society. Molecular Syndromology, 2016, 7, 251-261.	0.8	16
57	Focusing on cellular biomarkers: The endo-lysosomal pathway in Down syndrome. Progress in Brain Research, 2020, 251, 209-243.	1.4	16
58	On-chip hybridization kinetics for optimization of gene expression experiments. BioTechniques, 2008, 44, 109-117.	1.8	15
59	BDNF and DYRK1A Are Variable and Inversely Correlated in Lymphoblastoid Cell Lines from Down Syndrome Patients. Molecular Neurobiology, 2012, 46, 297-303.	4.0	15
60	<i>In vivo</i> ¹ H MRS study in microlitre voxels in the hippocampus of a mouse model of Down syndrome at 11.7 T. NMR in Biomedicine, 2014, 27, 1143-1150.	2.8	15
61	RORα Coordinates Thalamic and Cortical Maturation to Instruct Barrel Cortex Development. Cerebral Cortex, 2018, 28, 3994-4007.	2.9	15
62	The lipid phosphatase Synaptojanin 1 undergoes a significant alteration in expression and solubility and is associated with brain lesions in Alzheimer's disease. Acta Neuropathologica Communications, 2020, 8, 79.	5.2	15
63	Specific Triazine Herbicides Induce Amyloid-β42 Production. Journal of Alzheimer's Disease, 2016, 54, 1593-1605.	2.6	14
64	Aging rather than aneuploidy affects monoamine neurotransmitters in brain regions of Down syndrome mouse models. Neurobiology of Disease, 2017, 105, 235-244.	4.4	14
65	Translating molecular advances in Down syndrome and Fragile X syndrome into therapies. European Neuropsychopharmacology, 2018, 28, 675-690.	0.7	14
66	Editorial: Intellectual Disabilities in Down Syndrome from Birth and Throughout Life: Assessment and Treatment. Frontiers in Behavioral Neuroscience, 2016, 10, 120.	2.0	13
67	CYP46A1 protects against NMDA-mediated excitotoxicity in Huntington's disease: Analysis of lipid raft content. Biochimie, 2018, 153, 70-79.	2.6	13
68	Characterization of the Chicken Telokin Heterogeneity by Time-of-Flight Mass Spectrometryâ€. Biochemistry, 1997, 36, 11021-11026.	2.5	12
69	The 200-kb segmental duplication on human chromosome 21 originates from a pericentromeric dissemination involving human chromosomes 2, 18 and 13. Gene, 2003, 312, 51-59.	2.2	12
70	Neonatal therapy with clenbuterol and salmeterol restores spinogenesis and dendritic complexity in the dentate gyrus of the Ts65Dn model of Down syndrome. Neurobiology of Disease, 2020, 140, 104874.	4.4	12
71	Cholesterol in the senile plaque: often mentioned, never seen. Acta Neuropathologica, 2009, 117, 31-34.	7.7	11
72	Human subiculo-fornico-mamillary system in Alzheimer's disease: Tau seeding by the pillar of the fornix. Acta Neuropathologica, 2020, 139, 443-461.	7.7	10

#	Article	IF	CITATIONS
73	Transcriptomic Approach to Lesch-Nyhan Disease. Nucleosides, Nucleotides and Nucleic Acids, 2014, 33, 208-217.	1.1	8
74	Protein interacting with Amyloid Precursor Protein tail-1 (PAT1) is involved in early endocytosis. Cellular and Molecular Life Sciences, 2019, 76, 4995-5009.	5.4	8
75	Determination of Lipid Raft Partitioning of Fluorescently-tagged Probes in Living Cells by Fluorescence Correlation Spectroscopy (FCS). Journal of Visualized Experiments, 2012, , e3513.	0.3	6
76	Association of <i>APOE</i> -Independent Alzheimer Disease Polygenic Risk Score With Brain Amyloid Deposition in Asymptomatic Older Adults. Neurology, 2022, 99, .	1.1	6
77	Association of plasma Aβ40/Aβ42 ratio and brain Aβ accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's disease. Neurobiology of Aging, 2021, 107, 57-69.	3.1	5
78	Converting Alzheimer's Disease Map into a Heavyweight Ontology: A Formal Network to Integrate Data. Lecture Notes in Computer Science, 2019, , 207-215.	1.3	4
79	Cholesterol and ApoE in Alzheimer's disease. OCL - Oilseeds and Fats, Crops and Lipids, 2018, 25, D407.	1.4	1
80	Functional Genomics and Molecular Networks Gene Expression Regulations in Complex Diseases: Down Syndrome as a Case Study. , 2012, , 1-22.		0
81	P2-008: DYRK1A: A NOVEL BIOMARKER FOR ALZHEIMER'S DISEASE (AD) IDENTIFIED IN PLASMA AND LCLS FROM AD AND DS. , 2014, 10, P473-P473.		0
82	P2-007: ENDO-LYSOSOMAL ALTERATIONS IN DOWN SYNDROME BEFORE AND AFTER ALZHEIMER'S DISEASE. , 2014, 10, P473-P473.		0
83	Les déficits cognitifs dans la trisomie 21, de la naissance à la démence : mécanismes et traitements. Bulletin De L'Academie Nationale De Medecine, 2016, 200, 1543-1557.	0.0	Ο